Jun-20-25 05:50PM
|
|
Jun-16-25 05:09PM
|
|
11:20AM
|
|
Jun-13-25 05:50PM
|
|
12:15PM
|
|
08:42AM |
Loading… |
08:42AM
|
|
08:14AM
|
(Pharmaceutical Technology) |
07:37AM
|
|
12:39AM
|
|
Jun-12-25 07:25PM
|
|
11:19AM
|
|
08:15AM
|
|
04:25AM
|
|
Jun-11-25 10:20AM
|
|
10:20AM
|
|
07:00AM |
Loading… |
07:00AM
|
|
Jun-10-25 04:10PM
|
(Investor's Business Daily) |
10:19AM
|
|
10:10AM
|
|
09:46AM
|
|
08:18AM
|
|
Jun-09-25 07:12PM
|
|
06:09PM
|
(Investor's Business Daily) |
Jun-06-25 05:06PM
|
|
04:16PM
|
|
04:08PM
|
|
11:31AM
|
|
Jun-05-25 11:30AM
|
|
Jun-04-25 11:30AM
|
|
04:15AM
|
|
12:16PM |
Loading… |
Jun-03-25 12:16PM
|
|
09:23AM
|
|
07:59AM
|
(The Wall Street Journal) |
Jun-02-25 09:00PM
|
(The Wall Street Journal) |
04:41PM
|
|
02:35PM
|
|
01:30PM
|
|
12:09PM
|
|
11:39AM
|
|
10:38AM
|
|
09:49AM
|
|
09:46AM
|
(The Wall Street Journal) |
09:46AM
|
|
09:43AM
|
|
08:37AM
|
|
08:35AM
|
|
06:29AM
|
|
May-31-25 01:05PM
|
(Associated Press Finance) |
09:30AM
|
|
12:16AM
|
|
May-30-25 10:00AM
|
|
May-29-25 05:06PM
|
|
01:08PM
|
|
01:07PM
|
|
01:01PM
|
(Pharmaceutical Technology) |
11:08AM
|
|
11:01AM
|
|
09:06AM
|
|
07:45AM
|
|
07:36AM
|
|
May-28-25 11:43PM
|
|
08:01PM
|
(Associated Press Finance) |
06:06PM
|
|
May-27-25 07:00AM
|
|
May-26-25 11:35AM
|
|
11:01AM
|
|
09:41AM
|
|
06:30AM
|
|
May-23-25 07:53PM
|
|
04:19PM
|
|
04:19PM
|
|
04:05PM
|
|
May-22-25 12:35PM
|
|
10:48AM
|
|
07:15AM
|
|
May-21-25 08:31PM
|
|
08:15PM
|
|
04:58PM
|
|
11:57AM
|
(Pharmaceutical Technology) |
11:43AM
|
(Investor's Business Daily) |
11:43AM
|
(Investor's Business Daily) |
11:10AM
|
|
10:30AM
|
|
08:37AM
|
|
07:51AM
|
|
07:00AM
|
|
May-20-25 11:52PM
|
|
05:44PM
|
|
05:06PM
|
|
03:55PM
|
|
03:21PM
|
|
01:54PM
|
|
01:45PM
|
|
01:12PM
|
|
12:22PM
|
(Investor's Business Daily) |
11:56AM
|
|
May-19-25 10:27PM
|
|
05:18PM
|
|
09:42AM
|
|
May-16-25 04:35PM
|
|
|
|
|
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. |  |
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Hussain Abbas | Director | Jun 11 '25 | Sale | 28.00 | 312 | 8,736 | 580 | Jun 12 04:22 PM | Hussain Abbas | Director | Jun 11 '25 | Proposed Sale | 28.00 | 312 | 8,736 | | Jun 11 10:06 AM | Bancel Stephane | Chief Executive Officer | Mar 03 '25 | Buy | 31.22 | 160,314 | 5,004,318 | 9,210,686 | Mar 04 04:27 PM | SAGAN PAUL | Director | Mar 03 '25 | Buy | 31.76 | 31,620 | 1,004,251 | 312,027 | Mar 04 04:24 PM | Klinger Shannon Thyme | Chief Legal Officer | Dec 09 '24 | Sale | 44.68 | 529 | 23,637 | 20,446 | Dec 10 04:08 PM | Klinger Shannon Thyme | Officer | Dec 09 '24 | Proposed Sale | 44.68 | 529 | 23,637 | | Dec 09 03:18 PM | Klinger Shannon Thyme | Chief Legal Officer | Dec 03 '24 | Sale | 43.30 | 112 | 4,849 | 19,837 | Dec 04 05:11 PM | Hoge Stephen | President | Dec 03 '24 | Sale | 43.30 | 314 | 13,595 | 1,443,904 | Dec 04 05:08 PM | Klinger Shannon Thyme | Officer | Dec 03 '24 | Proposed Sale | 43.30 | 112 | 4,849 | | Dec 03 04:11 PM | Hoge Stephen | Officer | Dec 03 '24 | Proposed Sale | 43.30 | 314 | 13,595 | | Dec 03 03:23 PM | Mock James M | Chief Financial Officer | Nov 29 '24 | Sale | 42.79 | 1,420 | 60,761 | 11,066 | Dec 02 04:26 PM | Klinger Shannon Thyme | Chief Legal Officer | Nov 29 '24 | Sale | 42.79 | 1,418 | 60,675 | 19,717 | Dec 02 04:19 PM | Hoge Stephen | President | Nov 29 '24 | Sale | 42.79 | 291 | 12,452 | 1,443,567 | Dec 02 04:15 PM | Hoge Stephen | Officer | Nov 29 '24 | Proposed Sale | 42.79 | 291 | 12,452 | | Nov 29 03:54 PM | Klinger Shannon Thyme | Officer | Nov 29 '24 | Proposed Sale | 42.79 | 1,418 | 60,675 | | Nov 29 03:49 PM | Mock James M | Officer | Nov 29 '24 | Proposed Sale | 42.79 | 1,420 | 60,761 | | Nov 29 03:35 PM | Hoge Stephen | President | Nov 11 '24 | Sale | 46.10 | 277 | 12,771 | 1,443,248 | Nov 12 04:14 PM | Hoge Stephen | Officer | Nov 11 '24 | Proposed Sale | 46.10 | 277 | 12,771 | | Nov 12 09:27 AM | Mock James M | Chief Financial Officer | Oct 07 '24 | Sale | 60.12 | 715 | 42,986 | 9,505 | Oct 08 04:19 PM | Klinger Shannon Thyme | Chief Legal Officer | Sep 09 '24 | Sale | 73.57 | 551 | 40,539 | 18,154 | Sep 10 04:15 PM | Klinger Shannon Thyme | Officer | Sep 09 '24 | Proposed Sale | 73.57 | 551 | 40,539 | | Sep 09 03:29 PM | Klinger Shannon Thyme | Chief Legal Officer | Sep 03 '24 | Sale | 76.99 | 114 | 8,777 | 17,566 | Sep 04 05:42 PM | Hoge Stephen | President | Sep 03 '24 | Sale | 76.99 | 318 | 24,483 | 1,443,002 | Sep 04 04:26 PM | Klinger Shannon Thyme | Officer | Sep 03 '24 | Proposed Sale | 76.99 | 114 | 8,777 | | Sep 03 03:58 PM | Hoge Stephen | Officer | Sep 03 '24 | Proposed Sale | 76.99 | 318 | 24,482 | | Sep 03 03:42 PM | Mock James M | Chief Financial Officer | Aug 29 '24 | Sale | 78.03 | 162 | 12,640 | 8,767 | Aug 30 04:37 PM | Klinger Shannon Thyme | Chief Legal Officer | Aug 29 '24 | Sale | 78.03 | 162 | 12,640 | 17,447 | Aug 30 04:34 PM | Hoge Stephen | President | Aug 29 '24 | Sale | 78.03 | 300 | 23,408 | 1,442,668 | Aug 30 04:32 PM | Mock James M | Chief Financial Officer | Aug 28 '24 | Sale | 79.39 | 1,321 | 104,881 | 8,600 | Aug 29 04:45 PM | Klinger Shannon Thyme | Chief Legal Officer | Aug 28 '24 | Sale | 79.39 | 1,319 | 104,722 | 17,280 | Aug 29 04:03 PM | Klinger Shannon Thyme | Officer | Aug 29 '24 | Proposed Sale | 78.03 | 162 | 12,640 | | Aug 29 03:52 PM | Mock James M | Officer | Aug 29 '24 | Proposed Sale | 78.03 | 162 | 12,640 | | Aug 29 03:43 PM | Hoge Stephen | Officer | Aug 29 '24 | Proposed Sale | 78.03 | 300 | 23,408 | | Aug 29 03:38 PM | Mock James M | Officer | Aug 28 '24 | Proposed Sale | 79.39 | 1,321 | 104,881 | | Aug 28 04:47 PM | Klinger Shannon Thyme | Officer | Aug 28 '24 | Proposed Sale | 79.39 | 1,319 | 104,722 | | Aug 28 04:30 PM | Hoge Stephen | President | Aug 12 '24 | Sale | 84.10 | 254 | 21,363 | 1,442,357 | Aug 13 04:33 PM | Hoge Stephen | Officer | Aug 12 '24 | Proposed Sale | 84.10 | 254 | 21,363 | | Aug 12 04:05 PM | AFEYAN NOUBAR | Director | Jul 31 '24 | Sale | 119.96 | 15,000 | 1,799,443 | 2,224,015 | Aug 02 07:00 PM | NOUBAR B AFEYAN | Director | Jul 31 '24 | Proposed Sale | 118.84 | 15,000 | 1,782,600 | | Jul 31 04:18 PM | AFEYAN NOUBAR | Director | Jul 24 '24 | Sale | 117.80 | 15,000 | 1,766,972 | 2,239,015 | Jul 26 07:00 PM | AFEYAN NOUBAR | Director | Jul 17 '24 | Sale | 122.84 | 15,000 | 1,842,651 | 2,254,015 | Jul 19 07:00 PM | Hoge Stephen | President | Jul 15 '24 | Sale | 121.12 | 15,000 | 1,816,800 | 1,442,089 | Jul 16 04:08 PM | AFEYAN NOUBAR | Director | Jul 10 '24 | Sale | 117.08 | 15,000 | 1,756,177 | 2,269,015 | Jul 12 07:00 PM | Mock James M | Chief Financial Officer | Jul 08 '24 | Sale | 118.24 | 689 | 81,465 | 7,269 | Jul 09 04:34 PM | AFEYAN NOUBAR | Director | Jun 26 '24 | Sale | 127.22 | 15,000 | 1,908,293 | 2,284,015 | Jun 28 07:00 PM |
|